Stockscreener 앱 받기
1.29
8.40%
0.10
시장 영업 전:
1.31
0.02
+1.55%
전일 마감가:
$1.19
열려 있는:
$1.18
하루 거래량:
2.75M
Relative Volume:
3.58
시가총액:
$56.30M
수익:
$55,200
순이익/손실:
$-21.24M
주가수익비율:
-2.192
EPS:
-0.5885
순현금흐름:
$-19.37M
1주 성능:
+2.38%
1개월 성능:
-29.89%
6개월 성능:
-31.75%
1년 성능:
-34.52%
1일 변동 폭
$0.00
$0.00
1주일 범위
$1.15
$1.33
52주 변동 폭
$1.15
$4.34
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.29 | 56.30M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Gain Therapeutics Stock Price Forecast. Should You Buy GANX? - StockInvest.us
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance UK
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Price Target of $7.50 - MarketBeat
Form 8K Gain Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Form 8K Gain Therapeutics Inc For: 1 October By Investing.com - Investing.com Canada
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders - GlobeNewswire Inc.
Long-term data on a Parkinson’s drug candidate will be presented in Seoul. - Stock Titan
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca
Xenon Pharmaceuticals Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Modest Stock GainEarnings Quality Analysis - careplusvn.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy - Investing.com
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn
GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Put Flow Alert - dars.gov.et
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Common Gap - dars.gov.et
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Wyckoff Spring - www.dars.gov.et
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - MarketBeat
Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary - TradingView
Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug - Stock Titan
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gain Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows - scanx.trade
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall - TradingView
Gain Therapeutics 2Q Loss/Shr 11c >GANX - Moomoo
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update - Yahoo Finance
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsRetracement Entry - dars.gov.et
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsWeak Sell Signals - dars.gov.et
Gain Therapeutics Inc (GANX) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - finance.yahoo.com
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
3.98%
자본화:
|
볼륨(24시간):